PRCT Stock Forecast & Price Target

PROCEPT BioRobotics is supported by strong commercialization momentum, as Q1 sales of $83.1M grew 20% y/y, gross margin reached 65%, and adjusted EBITDA loss of $18M was better than expected, indicating improving operating leverage. Its AQUABEAM/HYDROS platform also benefits from favorable reimbursement dynamics, with HOPD Aquablation payment rising about 12% y/y to roughly $10.8K and still remaining more profitable than other resective BPH treatments, helping protect procedure economics. The company’s outlook is further strengthened by impressive domestic capital placements, all-time high ASPs of $485K, and the WATER IV prostate cancer study enrolling ahead of schedule, suggesting broader long-term market opportunity and management execution.

PROCEPT BioRobotics is facing a weakening fundamental backdrop as procedure growth has slowed over the last 4 qtrs, pressured by rising PAE adoption, sales force restructurings, and execution uncertainty around whether new leadership can lift utilization per system. Management’s Q2 revenue guidance sits about $2M below the Street, while 1Q procedures missed expectations and a steep 2H ramp is now required to reach 2026 procedure guidance. Despite a strong domestic capital placement quarter and an all-time high ASP up 14% sequentially, the stock’s roughly 2x EV/Sales valuation appears vulnerable if utilization does not improve and PAE headwinds intensify into ’27.